Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Evaluating Cancer Drugs in Patients With Central Nervous System Metastases

Evaluating Cancer Drugs in Patients With Central Nervous System Metastases This Viewpoint discusses the challenges and potential benefits of including patients with active central nerve system metastases in clinical trials that evaluate cancer drugs. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Evaluating Cancer Drugs in Patients With Central Nervous System Metastases

JAMA Oncology , Volume 7 (8) – Aug 15, 2021

Loading next page...
 
/lp/american-medical-association/evaluating-cancer-drugs-in-patients-with-central-nervous-system-i9g406fZ42
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2021.0180
Publisher site
See Article on Publisher Site

Abstract

This Viewpoint discusses the challenges and potential benefits of including patients with active central nerve system metastases in clinical trials that evaluate cancer drugs.

Journal

JAMA OncologyAmerican Medical Association

Published: Aug 15, 2021

References